Spirulina and Fibrinolysis.

The Fibrinolytic System: tPA, uPA, and Plasminogen

Fibrinolysis dissolves fibrin clots via plasmin (EC 3.4.21.7), generated from plasminogen (Glu-Plg; 791 aa) by two physiological plasminogen activators: tissue-type PA (tPA; PLAT; EC 3.4.21.68) and urokinase-type PA (uPA; PLAU; EC 3.4.21.73). tPA is predominantly endothelium-derived and fibrin-dependent: catalytic efficiency for plasminogen activation increases ~>500-fold when both tPA and plasminogen are bound to fibrin (Lys-Plg conformational change exposes Arg560-Val561 cleavage site; tPA F-domain/K2 kringle contacts fibrin Lys residues). uPA is secreted as single-chain pro-uPA (scuPA), converted to active two-chain uPA (tcuPA) by plasmin or kallikrein; uPA signals via uPAR (CD87; GPI-anchored) — the uPA-uPAR complex on cell surfaces amplifies localised plasminogen activation and drives matrix remodelling via pro-MMP activation. Plasmin cleaves fibrin at Lys/Arg residues generating FDPs including D-dimer (fragment D-D cross-link) and fragment E; plasmin also cleaves fibronectin, laminin, and activates pro-MMP-1/2/3/9.

PAI-1: The Master Fibrinolytic Brake

Plasminogen activator inhibitor-1 (PAI-1; SERPINE1) is the principal inhibitor of both tPA and uPA (k&sub2; ~10&sup7; M−s−¹). PAI-1 is a serpin functioning as a suicide substrate: its reactive centre loop (RCL; P1 Arg346–P1′ Met347) inserts into the tPA/uPA active site, forming a covalent acyl-enzyme intermediate that inactivates both. PAI-1 transcription is driven by NF-κB (κB sites at −180 and −590 bp of SERPINE1 promoter), TGF-β1 (SMAD3/4→SBE at −670 bp), and HIF-1α (HRE at −91 bp). Elevated PAI-1 is a biomarker of metabolic syndrome, obesity, and thrombotic risk; adipocytes express high PAI-1 under TNF-α/IL-6 via NF-κB.

Inhibitory Proteins: α2-Antiplasmin and TAFI

α2-antiplasmin (α2-AP; SERPINF2) inhibits free plasmin rapidly (k&sub2; ~4×10&sup7; M−s−¹) but acts 50–100-fold more slowly on fibrin-bound plasmin. α2-AP is cross-linked to fibrin by FXIIIa (Gln2 of α2-AP → fibrin Lys406), providing localised protection. Thrombin-activatable fibrinolysis inhibitor (TAFI; CPB2) is activated by the thrombin/thrombomodulin (TM; THBD) complex; TAFIa removes C-terminal Lys residues from partially degraded fibrin, eliminating plasminogen/tPA binding sites and dramatically slowing fibrinolysis. High TM (Nrf2-induced) drives both TAFIa (anti-fibrinolytic) and protein C activation (APC; anti-coagulant→PAI-1↓) — net effect depends on PAI-1 vs. TAFI balance.

Spirulina’s Mechanistic Actions on Fibrinolysis

• NF-κB ↓ → PAI-1 ↓: PCB → IKKβ Ser177 ↓ 30–50% → NF-κB nuclear ↓ → SERPINE1 κB occupancy ↓ → PAI-1 mRNA ↓ 25–45%; PAI-1 antigen ↓ 20–35% in LPS and high-fat-diet rodent models.
• AMPK → SIRT1 → AP-1 ↓ → SERPINE1 ↓: AMPK→SIRT1→FoxO1 deacetylation→FoxO1 nuclear→AP-1 suppression (c-Jun acetylation ↓)→AP-1-driven SERPINE1 ↓ 15–25%.
• Nrf2 → tPA ↑: PLAT promoter contains an ARE-like element; Nrf2 activation correlates with tPA +15–25% in endothelial cells under oxidative preconditioning. HO-1→CO→sGC→cGMP→PKG→NO reinforces tPA exocytosis from Weibel-Palade bodies.
• Nrf2 → THBD → APC → PAI-1 ↓: Nrf2→THBD +20–35%→thrombin-TM→APC→PAR-1/EPCR→NF-κB↓→PAI-1↓; APC also inactivates FVa/FVIIIa, limiting thrombin generation and thrombin-driven PAI-1 signalling.
• α2-AP and TAFI balance: Reduced thrombin (Nrf2-THBD-APC + NF-κB↓→TF ↓) lowers TAFIa; preserved α2-AP maintains protection against plasmin runaway; net: controlled fibrinolysis enhancement without haemorrhagic risk.
• GLA → PGI&sub2; → tPA exocytosis: Spirulina GLA→COX-1/2→PGI&sub2;→IP receptor→cAMP→PKA→tPA exocytosis ↑; PGI&sub2; also suppresses PAI-1 release via cAMP-driven CREB competing with NF-κB at SERPINE1 promoter.

Clinical Correlates and Dosing

Human studies: 4–8 g/day spirulina for 8–12 weeks lowered PAI-1 antigen 18–30% in obese and T2DM subjects (two controlled trials). D-dimer trended down 10–15% (non-significant in small cohorts). Fibrinogen ↓ 8–15% (reduced hepatic NF-κB-driven acute-phase synthesis). Animal data: tPA activity ↑ 20–30%; clot lysis time ↓ 15–25%; intravital thrombosis models → vessel occlusion time extended 20–35%. Interactions: anticoagulants (warfarin, DOACs) — additive anticoagulant effect via PAI-1↓ + TF↓ theoretically possible at high doses (>8 g/day); INR monitoring recommended in warfarin users. Antiplatelet agents (aspirin, clopidogrel) + spirulina: no reported haemorrhagic events in RCTs at standard doses.